Skip to content
Homepage
Author:
Sanofi Winthrop Industrie
Posted Date:
July 10, 2026
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi Winthrop Industrie
July 10, 2026
Press Release: Availability of the aide-mémoire for Q2 2026 results
Sanofi Winthrop Industrie
July 1, 2026
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi Winthrop Industrie
June 30, 2026
Press Release: Sanofi Foundation opens new chapter centered on future generations
Sanofi Winthrop Industrie
June 25, 2026
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi Winthrop Industrie
June 23, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi Winthrop Industrie
June 23, 2026
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi Winthrop Industrie
June 22, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi Winthrop Industrie
June 19, 2026
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi Winthrop Industrie
June 12, 2026
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi Winthrop Industrie
June 10, 2026
1
2
3
…
5
Next
